BioCentriq – a global cell-based therapy Contract Development and Manufacturing Organization (CDMO) – recently announced the successful completion of its latest round of fundraising, securing $29.2 million in capital investment. The funding round presents a significant milestone in BioCentriq’s mission to accelerate the delivery of innovative cell therapies by translating, optimizing, and scaling processes for GMP manufacture.
With this funding round, BioCentriq is poised to further accelerate its innovative capabilities in providing end-to-end solutions for cell therapy development and manufacturing. And the funds will be strategically deployed to enhance BioCentriq’s state-of-the-art facilities, invest in advanced technologies, and expand its talented team of experts to meet the increasing demand for scalable cell therapy solutions.
As a global leader in the cell therapy CDMO space, BioCentriq supports its partners in advancing life-changing therapies from concept to clinic. And the company’s comprehensive suite of services includes process development, manufacturing, and analytical testing ensuring seamless and efficient development of cell-based therapies for diverse therapeutic areas.
The successful funding round comes at a pivotal time in the cell therapy landscape, with increasing interest and investment. And BioCentriq is well-positioned to capitalize on this momentum, utilizing its expanded resources to further propel advancements in cell-based therapeutic development and manufacturing.
KEY QUOTE:
“We are thrilled to announce the successful completion of our latest fundraising round, which reflects the confidence of our investors in BioCentriq’s vision and capabilities. This capital injection positions us strongly to continue driving innovation in cell therapy development, enabling our partners to bring transformative treatments to patients around the world.”
— James Park, BioCentriq Interim CEO and Chairman of the Board
